Literature DB >> 26392487

In Vitro Activities of Ceftazidime-Avibactam, Aztreonam-Avibactam, and a Panel of Older and Contemporary Antimicrobial Agents against Carbapenemase-Producing Gram-Negative Bacilli.

Shawn Vasoo1, Scott A Cunningham2, Nicolynn C Cole2, Peggy C Kohner2, Sanjay R Menon3, Kevin M Krause4, Kelly A Harris4, Partha P De3, Tse Hsien Koh5, Robin Patel6.   

Abstract

Among 177 carbapenemase-producing Gram-negative bacilli (108 KPC, 32 NDM, 11 IMP, 8 OXA-48, 4 OXA-181, 2 OXA-232, 5 IMI, 4 VIM, and 3 SME producers), aztreonam-avibactam was active against all isolates except two NDM producers with elevated MICs of 8/4 and 16/4 mg/liter; ceftazidime-avibactam was active against all KPC-, IMI-, SME-, and most OXA-48 group-producing isolates (93%) but not metallo-β-lactamase producers. Among older and contemporary antimicrobials, the most active were colistin, tigecycline, and fosfomycin, with overall susceptibilities of 88%, 79%, and 78%, respectively.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26392487      PMCID： PMC4649150          DOI： 10.1128/AAC.02019-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  19 in total

1.  Avibactam and class C β-lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance.

Authors:  S D Lahiri; M R Johnstone; P L Ross; R E McLaughlin; N B Olivier; R A Alm
Journal:  Antimicrob Agents Chemother       Date:  2014-07-14       Impact factor: 5.191

2.  Avibactam and inhibitor-resistant SHV β-lactamases.

Authors:  Marisa L Winkler; Krisztina M Papp-Wallace; Magdalena A Taracila; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2015-02-17       Impact factor: 5.191

3.  Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam/avibactam: role of a novel insertion in PBP3.

Authors:  Richard A Alm; Michele R Johnstone; Sushmita D Lahiri
Journal:  J Antimicrob Chemother       Date:  2015-01-28       Impact factor: 5.790

4.  Rapid and simultaneous detection of genes encoding Klebsiella pneumoniae carbapenemase (blaKPC) and New Delhi metallo-β-lactamase (blaNDM) in Gram-negative bacilli.

Authors:  Scott A Cunningham; Tabassum Noorie; Daniele Meunier; Neil Woodford; Robin Patel
Journal:  J Clin Microbiol       Date:  2013-01-23       Impact factor: 5.948

5.  Acquired carbapenemases in Enterobactericeae in Singapore, 1996-2012.

Authors:  Tse Hsien Koh; Delphine Cao; Quek Yen Shan; Anna Bacon; Li-Yang Hsu; Eng Eong Ooi
Journal:  Pathology       Date:  2013-10       Impact factor: 5.306

6.  Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases.

Authors:  P R S Lagacé-Wiens; F Tailor; P Simner; M DeCorby; J A Karlowsky; A Walkty; D J Hoban; G G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2011-02-28       Impact factor: 5.191

7.  Molecular characterization of NDM-1 producing Enterobacteriaceae isolates in Singapore hospitals.

Authors:  Jeanette Teo; Grace Ngan; Michelle Balm; Roland Jureen; Prabha Krishnan; Raymond Lin
Journal:  Western Pac Surveill Response J       Date:  2012-03-29

8.  Characterization of VIM-2, a carbapenem-hydrolyzing metallo-beta-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France.

Authors:  L Poirel; T Naas; D Nicolas; L Collet; S Bellais; J D Cavallo; P Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

Review 9.  New β-lactamase inhibitors: a therapeutic renaissance in an MDR world.

Authors:  Sarah M Drawz; Krisztina M Papp-Wallace; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2013-12-30       Impact factor: 5.191

10.  Emergence of clinical Klebsiella pneumoniae producing OXA-232 carbapenemase in Singapore.

Authors:  J W P Teo; A Kurup; R T P Lin; K T Hsien
Journal:  New Microbes New Infect       Date:  2013-09-18
View more
  36 in total

1.  Coproduction of KPC-18 and VIM-1 Carbapenemases by Enterobacter cloacae: Implications for Newer β-Lactam-β-Lactamase Inhibitor Combinations.

Authors:  Gina K Thomson; James W Snyder; Christi L McElheny; Kenneth S Thomson; Yohei Doi
Journal:  J Clin Microbiol       Date:  2015-12-30       Impact factor: 5.948

2.  Evaluation of the Check-Points Check MDR CT103 and CT103 XL Microarray Kits by Use of Preparatory Rapid Cell Lysis.

Authors:  Scott A Cunningham; Shawn Vasoo; Robin Patel
Journal:  J Clin Microbiol       Date:  2016-02-17       Impact factor: 5.948

3.  In Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015.

Authors:  James A Karlowsky; Krystyna M Kazmierczak; Boudewijn L M de Jonge; Meredith A Hackel; Daniel F Sahm; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

4.  In Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014).

Authors:  Boudewijn L M de Jonge; James A Karlowsky; Krystyna M Kazmierczak; Douglas J Biedenbach; Daniel F Sahm; Wright W Nichols
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

Review 5.  Carbapenem-Resistant Enterobacteriaceae in Solid Organ Transplantation: Management Principles.

Authors:  Olivia Smibert; Michael J Satlin; Anoma Nellore; Anton Y Peleg
Journal:  Curr Infect Dis Rep       Date:  2019-06-10       Impact factor: 3.725

6.  Aztreonam-Avibactam Combination Restores Susceptibility of Aztreonam in Dual-Carbapenemase-Producing Enterobacteriaceae.

Authors:  Ka Lip Chew; Michelle K L Tay; Bernadette Cheng; Raymond T P Lin; Sophie Octavia; Jeanette W P Teo
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

7.  Susceptibility of Imipenem-Susceptible but Meropenem-Resistant blaIMP-6-Carrying Enterobacteriaceae to Various Antibacterials, Including the Siderophore Cephalosporin Cefiderocol.

Authors:  Sachi Kanazawa; Takafumi Sato; Naoki Kohira; Tsukasa Ito-Horiyama; Masakatsu Tsuji; Yoshinori Yamano
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

8.  Diversity of resistance mechanisms in carbapenem-resistant Enterobacteriaceae at a health care system in Northern California, from 2013 to 2016.

Authors:  Fiona Senchyna; Rajiv L Gaur; Johanna Sandlund; Cynthia Truong; Guillaume Tremintin; Dietmar Kültz; Carlos A Gomez; Fiona B Tamburini; Tessa Andermann; Ami Bhatt; Isabella Tickler; Nancy Watz; Indre Budvytiene; Gongyi Shi; Fred C Tenover; Niaz Banaei
Journal:  Diagn Microbiol Infect Dis       Date:  2018-10-13       Impact factor: 2.803

Review 9.  Pharmacological aspects and spectrum of action of ceftazidime-avibactam: a systematic review.

Authors:  Felipe Francisco Tuon; Jaime L Rocha; Marcelo R Formigoni-Pinto
Journal:  Infection       Date:  2017-11-07       Impact factor: 3.553

10.  In Vitro Activity of Imipenem-Relebactam and Ceftolozane-Tazobactam against Resistant Gram-Negative Bacilli.

Authors:  Suzannah M Schmidt-Malan; Avisya J Mishra; Ammara Mushtaq; Cassandra L Brinkman; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.